Holen Sie sich die Stockscreener-App
3.18
1.92%
0.06
Handel nachbörslich:
3.18
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.12
Offen:
$3.11
24-Stunden-Volumen:
1.28M
Relative Volume:
0.68
Marktkapitalisierung:
$304.17M
Einnahmen:
$829.00M
Nettoeinkommen (Verlust:
$-399.90M
KGV:
-0.7368
EPS:
-4.3159
Netto-Cashflow:
$-23.20M
1W Leistung:
-1.24%
1M Leistung:
-41.65%
6M Leistung:
-31.02%
1J Leistung:
-46.37%
1-Tages-Spanne:
$3.09
$3.2699
1-Wochen-Bereich:
$3.00
$3.2699
52-Wochen-Spanne:
$2.74
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
3.18 | 307.99M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
630.70 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.68 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
338.70 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
157.69 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
262.38 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect - ACCESS Newswire
Burning Rock and Myriad Announce Global Strategic Technology Lice - The National Law Review
MYGN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Myriad Genetics Inc. - accessnewswire.com
MYGN Maintained by Stephens & Co. -- Price Target Lowered to $3. - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Marquis Who's Who Honors Ben Wheeler for Expertise in Finance and Healthcare - 24-7 Press Release Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Myriad Genetics (MYGN): Glenview Capital and Larry Robbins report exit from stake - Stock Titan
Myriad Genetics (MYGN): Vestal Point Capital discloses 6.1% stake in 13G filing - Stock Titan
Myriad Genetics Faces Multiple Investor Investigations - stl.news
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
Dimensional Fund Advisors LP Reduces Stake in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Assenagon Asset Management S.A. Reduces Holdings in Myriad Genetics, Inc. $MYGN - MarketBeat
3 Healthcare Stocks with Open Questions - Yahoo Finance
Price-Driven Insight from (MYGN) for Rule-Based Strategy - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, In - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
Myriad Genetics (MYGN) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect - accessnewswire.com
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law - FinancialContent
Myriad Genetics (NASDAQ:MYGN) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Myriad Genetics Inc (MYD.HA) stock price, news, quote and history - Yahoo Finance Australia
State Street Corporation (NYSE: STT) discloses 5.3% holding in Myriad Genetics - Stock Titan
Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating Through a Challenging Landscape with 69.36% Potential Upside - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN) - globenewswire.com
Myriad Genetics (NASDAQ:MYGN) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP - GlobeNewswire
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN) - Business Wire
MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics - Morningstar
Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel - GlobeNewswire
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.34, Implies 87% Upside - TradingView
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN) - PR Newswire
MYGN Slides As Myriad Genetics Slashes 2026 Revenue Outlook - timothysykes.com
Myriad Genetics (MYGN) Missed Q2 And Cut Guidance, Is It Still 54% Below Fair Value? - Yahoo Finance
MYGN Stock Slides As Myriad Genetics Slashes 2026 Outlook - timothysykes.com
Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down (NASDAQ:MYGN) - Seeking Alpha
Myriad Genetics, Inc. Stock 12‑Month Price Target Cut to $5.75, Implies 7% Upside - TradingView
Myriad Genetics (NASDAQ:MYGN) Posts Earnings Results, Misses Estimates By $0.22 EPS - MarketBeat
MYRIAD GENETICS ($MYGN) Releases Q2 2026 Earnings - Quiver Quantitative
Myriad: Q2 Earnings Snapshot - KVUE
Wells Fargo Maintains Myriad Genetics(MYGN.US) With Hold Rating, Maintains Target Price $5.5 - Moomoo
Myriad Genetics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds. - Business Insider
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):